Biostatistics (2004), 5, 3, pp. 465-481
Biostatistics Vol. 5 No. 3 © Oxford University Press 2004; all rights reserved.
Patterns of treatment effects in subsets of patients in clinical trials
Department of Biostatistics, Harvard School of Public Health and Dana-Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, USA
bonetti{at}jimmy.harvard.edu
We discuss the practice of examining patterns of treatment effects across overlapping patient subpopulations. In particular, we focus on the case in which patient subgroups are defined to contain patients having increasingly larger (or smaller) values of one particular covariate of interest, with the intent of exploring the possible interaction between treatment effect and that covariate. We formalize these subgroup approaches (STEPP: subpopulation treatment effect pattern plots) and implement them when treatment effect is defined as the difference in survival at a fixed time point between two treatment arms. The joint asymptotic distribution of the treatment effect estimates is derived, and used to construct simultaneous confidence bands around the estimates and to test the null hypothesis of no interaction. These methods are illustrated using data from a clinical trial conducted by the International Breast Cancer Study Group, which demonstrates the critical role of estrogen receptor content of the primary breast cancer for selecting appropriate adjuvant therapy. The considerations are also relevant for general subset analysis, since information from the same patients is typically used in the estimation of treatment effects within two or more subgroups of patients defined with respect to different covariates.
Keywords: Breast cancer; STEPP; Subset analysis; Survival data; Treatment-covariate interaction
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  M. Rabaglio, Z. Sun, K. N. Price, M. Castiglione-Gertsch, H. Hawle, B. Thurlimann, H. Mouridsen, M. Campone, J. F. Forbes, R. J. Paridaens, et al. Bone fractures among postmenopausal patients with endocrine-responsive early breast cancer treated with 5 years of letrozole or tamoxifen in the BIG 1-98 trial Ann. Onc., September 1, 2009; 20(9): 1489 - 1498. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Colleoni, Z. Sun, G. Martinelli, R. L. Basser, A. S. Coates, R. D. Gelber, M. D. Green, F. Peccatori, S. Cinieri, S. Aebi, et al. The effect of endocrine responsiveness on high-risk breast cancer treated with dose-intensive chemotherapy: results of International Breast Cancer Study Group Trial 15-95 after prolonged follow-up Ann. Onc., August 1, 2009; 20(8): 1344 - 1351. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Bonetti, B. F. Cole, and R. D. Gelber Another STEPP in the Right Direction J. Clin. Oncol., August 1, 2008; 26(22): 3813 - 3814. [Full Text] [PDF]
|
|
|
|
|
|
D. Crivellari, Z. Sun, A. S. Coates, K. N. Price, B. Thurlimann, H. Mouridsen, L. Mauriac, J. F. Forbes, R. J. Paridaens, M. Castiglione-Gertsch, et al. Letrozole Compared With Tamoxifen for Elderly Patients With Endocrine-Responsive Early Breast Cancer: The BIG 1-98 Trial J. Clin. Oncol., April 20, 2008; 26(12): 1972 - 1979. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Royston and W. Sauerbrei Interactions Between Treatment and Continuous Covariates: A Step Toward Individualizing Therapy J. Clin. Oncol., March 20, 2008; 26(9): 1397 - 1399. [Full Text] [PDF]
|
|
|
|
|
|
G. Viale, M. M. Regan, E. Maiorano, M. G. Mastropasqua, R. Golouh, T. Perin, R. W. Brown, A. Kovacs, K. Pillay, C. Ohlschlegel, et al. Chemoendocrine Compared With Endocrine Adjuvant Therapies for Node-Negative Breast Cancer: Predictive Value of Centrally Reviewed Expression of Estrogen and Progesterone Receptors--International Breast Cancer Study Group J. Clin. Oncol., March 20, 2008; 26(9): 1404 - 1410. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. F. Hayes Markers for Predicting and Evaluating Response to Therapy for Breast Cancer ASCO Educational Book, January 1, 2008; 2008(1): 30 - 34. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Karlsson, B. F. Cole, K. N. Price, A. S. Coates, M. Castiglione-Gertsch, B. A. Gusterson, E. Murray, J. Lindtner, J. P. Collins, S. B. Holmberg, et al. The Role of the Number of Uninvolved Lymph Nodes in Predicting Locoregional Recurrence in Breast Cancer J. Clin. Oncol., May 20, 2007; 25(15): 2019 - 2026. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. D. Allison, B. J. Bryant, S. Vasu, and S. F. Leitman Iron Reduction and Cardiovascular Outcomes JAMA, May 16, 2007; 297(19): 2075 - 2076. [Full Text] [PDF]
|
|
|
|
|
|
J. Bernhard, D. Zahrieh, M. Castiglione-Gertsch, C. Hurny, R. D. Gelber, J. F. Forbes, E. Murray, J. Collins, S. Aebi, B. Thurlimann, et al. Adjuvant Chemotherapy Followed By Goserelin Compared With Either Modality Alone: The Impact on Amenorrhea, Hot Flashes, and Quality of Life in Premenopausal Patients--The International Breast Cancer Study Group Trial VIII J. Clin. Oncol., January 20, 2007; 25(3): 263 - 270. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Colleoni, S. Li, R. D. Gelber, A. S. Coates, M. Castiglione-Gertsch, K. N. Price, J. Lindtner, C.-M. Rudenstam, D. Crivellari, J. Collins, et al. Timing of CMF chemotherapy in combination with tamoxifen in postmenopausal women with breast cancer: role of endocrine responsiveness of the tumor Ann. Onc., May 1, 2005; 16(5): 716 - 725. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Tondini and R. Labianca Tailoring a tailored treatment: the importance of fine-tuning on the patient Ann. Onc., May 1, 2005; 16(5): 683 - 685. [Full Text] [PDF]
|
|